Incyte (INCY) Announces FDA Approval of Pemazyre
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 1/28/2023
- Wall Street ends higher, notches weekly gains as Fed meeting looms
- Intel pares losses but sheds $9 billion in value on dire outlook, dividend concerns
- Analysts rush to cut Intel (INTC) price targets following weaker than expected Q1 guidance
- Meta (META): Apple's privacy policy change 'no longer a drag on earnings', now a tailwind YoY - WSJ
- Lucid Group (LCID) doubles on Saudi rumors
- Lucid Group (LCID) halted again on volatility after 56% mid-day surge on rumors
- Bed Bath & Beyond (BBBY) Names Carol Flaton to Board of Directors
- Lucid Group (LCID) on Watch Following Chatter
- Hanryu Holdings (HRYU) Announces Proposed IPO
- Wall Street ends higher, notches weekly gains as Fed meeting looms
- Midday movers: American Express, Tesla, Intel and more
- Intel tumbles in premarket; Hasbro, Chevron also down
- After-hours movers: Intel sinks on humiliating guidance, Visa gains on earnings
- Midday movers: Tesla, Chevron, Southwest Airlines and more
- After-hours movers: Tesla ticks up on beat, Chevron jumps on massive buyback
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
August 26, 2022 10:00 AM EDTThis marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement
Pemazyre is the only FGFR inhibitor with multiple indications
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre® (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or... More
